Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/treatment-of-philadelphia-chromosome-positive-acute-lymphoblastic-Ssv2FqbfQQ
References (135)
-
O. Ottmann, R. Larson, H. Kantarjian, P. Coutre, M. Baccarani, A. Hochhaus, Dong-Wook Kim, Xiaolin Fan, S. Novick, F. Giles (2013)
Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome—positive acute lymphoblastic leukemiaLeukemia, 27
-
Charlotte Rolny, I. Nilsson, P. Magnusson, A. Armulik, Lars Jakobsson, P. Wentzel, P. Lindblom, J. Norlin, C. Betsholtz, R. Heuchel, M. Welsh, L. Claesson-Welsh (2006)
Platelet-derived growth factor receptor-beta promotes early endothelial cell differentiation.Blood, 108 6
-
J. Sierra, J. Radich, J. Hansen, P. Martin, E. Petersdorf, J. Bjerke, E. Bryant, R. Nash, J. Sanders, R. Storb, K. Sullivan, F. Appelbaum, C. Anasetti (1997)
Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.Blood, 90 4
-
C. Mullighan, C. Miller, I. Radtke, Letha Phillips, J. Dalton, Jing Ma, D. White, T. Hughes, M. Beau, C. Pui, M. Relling, S. Shurtleff, J. Downing (2008)
BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of IkarosNature, 453
-
M. Vignetti, P. Fazi, G. Cimino, G. Martinelli, F. Raimondo, F. Ferrara, G. Meloni, A. Ambrosetti, G. Quarta, L. Pagano, G. Rege‐Cambrin, L. Elia, R. Bertieri, L. Annino, R. Foà, M. Baccarani, F. Mandelli (2007)
Gruppo Italiano Malattie Ematologiche dell ' Adulto ( GIMEMA ) acute lymphoblastic leukemia without additional chemotherapy : results survival in elderly Philadelphia chromosome – positive patients with Imatinib plus steroids induces complete remissions and prolonged -
M. Yanada, J. Takeuchi, I. Sugiura, H. Akiyama, N. Usui, F. Yagasaki, Tohru Kobayashi, Y. Ueda, M. Takeuchi, S. Miyawaki, A. Maruta, N. Emi, Y. Miyazaki, S. Ohtake, I. Jinnai, K. Matsuo, T. Naoe, R. Ohno (2006)
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 3
-
M. Wetzler, D. Watson, W. Stock, G. Koval, Flora Mulkey, E. Hoke, J. McCarty, W. Blum, B. Powell, G. Marcucci, C. Bloomfield, C. Linker, R. Larson (2014)
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)Haematologica, 99
-
S. Soverini, Sabrina Colarossi, A. Gnani, F. Castagnetti, G. Rosti, C. Bosi, S. Paolini, M. Rondoni, P. Piccaluga, F. Palandri, P. Giannoulia, G. Marzocchi, S. Luatti, N. Testoni, I. Iacobucci, D. Cilloni, G. Saglio, M. Baccarani, G. Martinelli (2007)
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.Haematologica, 92 3
-
J. Rowe, G. Buck, A. Burnett, R. Chopra, P. Wiernik, S. Richards, H. Lazarus, I. Franklin, M. Litzow, N. Ciobanu, H. Prentice, J. Durrant, M. Tallman, A. Goldstone (2005)
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.Blood, 106 12
-
H Pfeifer, O Spinelli, J Cayuela (2012)
International standardization of minimal residual disease assessment for Philadelphia chromosome positive acute lymphoblastic leukemia expressing minor-BCR-ABL: updated results of EuroMRD. (Abstract)Haemtologica, 97
-
S. Soverini, C. Benedittis, K. Polakova, A. Broučková, C. Papayannidis, P. Bresciani, V. Coluccio, I. Iacobucci, C. Venturi, M. Luppi, E. Ottaviani, F. Cattina, R. Foà, A. Vitale, D. Russo, M. Baccarani, G. Martinelli (2012)
Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based TherapiesBlood, 120
-
H. Esperou, J. Boiron, J. Cayuela, O. Blanchet, M. Kuentz, J. Jouet, N. Milpied, J. Cahn, C. Faucher, J. Bourhis, M. Michallet, M. Tanguy, J. Vernant, J. Gabert, P. Bordigoni, N. Ifrah, A. Baruchel, H. Dombret, for Cellulaire (2003)
A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation SocietyBone Marrow Transplantation, 31
-
R. Arnold, G. Massenkeil, M. Bornhäuser, G. Ehninger, D. Beelen, A. Fauser, U. Hegenbart, B. Hertenstein, A. Ho, W. Knauf, Kolb Hj, K. Kolbe, H. Sayer, R. Schwerdtfeger, H. Wandt, D. Hoelzer (2002)
Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced diseaseLeukemia, 16
-
S. Mustjoki, P. Rousselot, S. Jalkanen, A. Kreutzman, T. Melo, Anna-Maria Lahesmaa, S. Hautaniemi, M. Molimard, Richard Smykla, F. Lee, J. Vakkila, K. Porkka (2010)
Dasatinib Induces a Rapid, Dose-Controllable Mobilization of Cytotoxic Lymphocytes: A Novel Immunomodulatory Effect Associated with Prolonged Therapy Responses In Advanced Leukemia.Blood, 116
-
J. Ribera, A. Oriol, Marcos González, B. Vidriales, S. Brunet, J. Esteve, E. Potro, C. Rivas, M. Moreno, M. Tormo, V. Martín-Reina, J. Sarrá, R. Parody, J. Oteyza, E. Bureo, M. Bernal (2010)
Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trialHaematologica, 95
-
S. Soverini, G. Martinelli, Sabrina Colarossi, A. Gnani, F. Castagnetti, G. Rosti, C. Bosi, S. Paolini, M. Rondoni, P. Piccaluga, F. Palandri, P. Giannoulia, G. Marzocchi, S. Luatti, N. Testoni, I. Iacobucci, D. Cilloni, G. Saglio, M. Baccarani (2006)
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 33
-
A. Fielding, J. Rowe, S. Richards, G. Buck, A. Moorman, I. Durrant, D. Marks, A. McMillan, M. Litzow, H. Lazarus, L. Foroni, G. Dewald, I. Franklin, S. Luger, E. Paietta, P. Wiernik, M. Tallman, A. Goldstone (2009)
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993.Blood, 113 19
-
B. Patel, L. Rai, G. Buck, S. Richards, Yeasmin Mortuza, W. Mitchell, G. Gerrard, A. Moorman, V. Duke, A. Hoffbrand, A. Fielding, A. Goldstone, L. Foroni (2010)
Minimal residual disease is a significant predictor of treatment failure in non T‐lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993British Journal of Haematology, 148
-
H. Shin, J. Chung, G. Cho (2005)
Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leukemiaBone Marrow Transplantation, 36
-
S. Branford, Z. Rudzki, Sonya Walsh, A. Grigg, C. Arthur, K. Taylor, R. Herrmann, K. Lynch, T. Hughes (2002)
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.Blood, 99 9
-
D. Thomas, S. Faderl, J. Cortes, S. O'brien, F. Giles, S. Kornblau, G. Garcia-Manero, M. Keating, M. Andreeff, S. Jeha, M. Beran, S. Verstovsek, S. Pierce, L. Letvak, A. Salvado, R. Champlin, M. Talpaz, H. Kantarjian (2004)
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.Blood, 103 12
-
M Vignetti, P Fazi, G Cimino (2007)
Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocolBlood, 109
-
V. Pullarkat, M. Slovak, K. Kopecky, S. Forman, F. Appelbaum (2008)
Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.Blood, 111 5
-
P. Rousselot, M. Coudé, F. Huguet, M. Lafage, T. Leguay, C. Salanoubat, F. Witz, M. Alexis, M. Janvier, M. Hunault, P. Agapé, C. Berthou, E. Jourdan, J. Fernandes, L. Sutton, A. Banos, O. Reman, B. Lioure, J. Cayuela, S. Hayette, N. Gökbuget, D. Hoelzer, A. Delannoy, C. Gambacorti-Passerini, R. Bassan, J. Ribera, S. Giebel, H. Dombret, O. Ottmann (2012)
Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line Treatment in Patients with De Novo Philadelphia Positive ALL Aged 55 and Over: Final Results of the EWALL-Ph-01 StudyBlood, 120
-
T. Leguay, F. Witz, S. Botton, J. Gabert, J. Cayuela, E. Macintyre, C. Preudhomme, N. Fegueux, X. Thomas, J. Cahn, M. Escoffre, A. Delannoy, N. Ifrah, H. Dombret, A. Pigneux (2006)
Post-Remission Therapy with Imatinib and HAM Improve MRD before Tansplant for Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL): Results of the GRAALL AFR03 Study.Blood, 108
-
A. Stein, J. Palmer, M. O'donnell, N. Kogut, R. Spielberger, M. Slovak, N. Tsai, D. Senitzer, D. Snyder, Sandra Thomas, S. Forman (2009)
Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 15 11
-
H. Pfeifer, Christoph Wettner, B. Wassmann, Aristoteles Giagounidis, M. Stelljes, U. Duehrsen, M. Schmalzing, M. Schaich, M. Wit, A. Ganser, W. Gassmann, M. Pfreundschuh, N. Haertel, K. Wendelin, M. Schmid, H. Beck, J. Dengler, H. Horst, M. Lübbert, H. Serve, N. Goekbuget, D. Hoelzer, O. Ottmann (2012)
Long Term Follow-up of 121 Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Treated in Prospective GMALL Trials Supports a Greater Emphasis On Allogeneic SCT as Definitive Postremission Therapy.Blood, 120
-
D. Choudhary, P. Mishra, Ravi Kumar, M. Mahapatra, V. Choudhry (2006)
Pregnancy on imatinib: fatal outcome with meningocele.Annals of oncology : official journal of the European Society for Medical Oncology, 17 1
-
H. Kantarjian, Dong-Wook Kim, J. Pinilla-Ibarz, P. Coutre, R. Paquette, C. Chuah, F. Nicolini, J. Apperley, H. Khoury, M. Talpaz, J. Dipersio, D. DeAngelo, E. Abruzzese, D. Réa, M. Baccarani, Martin Müller, C. Gambacorti-Passerini, S. Wong, S. Lustgarten, V. Rivera, T. Clackson, C. Turner, F. Haluska, F. Guilhot, M. Deininger, A. Hochhaus, T. Hughes, J. Goldman, N. Shah, J. Cortes (2012)
Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE TrialBlood, 120
-
B. Wassmann, H. Pfeifer, N. Goekbuget, D. Beelen, J. Beck, M. Stelljes, M. Bornhäuser, Albrecht Reichle, J. Perz, R. Haas, Arnold Ganser, M. Schmid, Lothar Kanz, Georg Lenz, M. Kaufmann, A. Binckebanck, P. Brück, R. Reutzel, H. Gschaidmeier, Stefan Schwartz, D. Hoelzer, O. Ottmann (2006)
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).Blood, 108 5
-
A. Fielding, G. Buck, H. Lazarus, M. Litzow, S. Luger, D. Marks, A. McMillan, A. Moorman, E. Paietta, S. Richards, M. Tallman, J. Rowe, A. Goldstone (2010)
Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 TrialBlood, 116
-
K. Schultz, W. Bowman, A. Aledo, W. Slayton, H. Sather, M. Devidas, Chenguang Wang, S. Davies, P. Gaynon, M. Trigg, R. Rutledge, Laura Burden, D. Jorstad, A. Carroll, N. Heerema, N. Winick, M. Borowitz, S. Hunger, W. Carroll, B. Camitta (2009)
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 31
-
Joseph Roberts, Andrea Lengi, Stephanie Brown, Min Chen, Yong-Jie Zhou, John 'shea, Rebecca Buckley (2002)
Clinical Observations, Interventions, and Therapeutic Trials -
A. Oriol, S. Vives, J. Hernández-Rivas, M. Tormo, I. Heras, C. Rivas, C. Bethencourt, F. Moscardó, J. Bueno, C. Grande, E. Potro, R. Guàrdia, S. Brunet, J. Bergua, T. Bernal, M. Moreno, C. Calvo, P. Bastida, E. Feliú, J. Ribera (2010)
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study GroupHaematologica, 95
-
B. Gleissner, N. Gökbuget, C. Bartram, B. Janssen, H. Rieder, J. Janssen, C. Fonatsch, A. Heyll, D. Voliotis, J. Beck, T. Lipp, G. Munzert, J. Maurer, D. Hoelzer, E. Thiel (2002)
Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis.Blood, 99 5
-
H. Kolb, A. Schattenberg, J. Goldman, B. Hertenstein, N. Jacobsen, W. Arcese, P. Ljungman, A. Ferrant, L. Verdonck, D. Niederwieser, F. Rhee, J. Mittermueller, T. Witte, E. Holler, H. Ansari (1995)
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.Blood, 86 5
-
L. Secker-Walker, J. Craig, J. Hawkins, A. Hoffbrand (1991)
Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance.Leukemia, 5 3
-
F. Gruber, S. Mustjoki, K. Porkka (2009)
Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome‐positive acute lymphoblastic leukaemiaBritish Journal of Haematology, 145
-
M. Burke, Q. Cao, B. Trotz, B. Weigel, Ashish Kumar, Angela Smith, M. Verneris (2009)
Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome‐positive acute lymphoblastic leukemia (ALL)Pediatric Blood & Cancer, 53
-
M. Mohty, M. Labopin, Reza Tabrizzi, N. Theorin, A. Fauser, A. Rambaldi, J. Maertens, S. Slavin, I. Majolino, A. Nagler, D. Blaise, V. Rocha (2008)
Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow TransplantationHaematologica, 93
-
H.Alejandro Preti, S. O’Brien, S. Giralt, M. Beran, S. Pierce, H. Kantarjian (1994)
Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients.The American journal of medicine, 97 1
-
A. Labarthe, P. Rousselot, F. Huguet-Rigal, E. Delabesse, F. Witz, S. Maury, D. Réa, J. Cayuela, M. Vekemans, O. Reman, A. Buzyn, A. Pigneux, M. Escoffre, Y. Chalandon, E. Macintyre, V. Lheritier, J. Vernant, X. Thomas, N. Ifrah, H. Dombret (2007)
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome – positive acute lymphoblastic leukemia : results of the GRAAPH-2003 study -
Y. Chelghoum, N. Vey, E. Raffoux, F. Huguet, A. Pigneux, B. Witz, C. Pautas, S. Botton, D. Guyotat, B. Lioure, N. Fegueux, F. Garban, H. Saad, X. Thomas (2005)
Acute leukemia during pregnancyCancer, 104
-
P. Rousselot, J. Cayuela, S. Hayette, C. Récher, T. Leguay, C. Salanoubat, F. Witz, M. Alexis, M. Hunault, M. Janvier, P. Agapé, C. Berthou, E. Jourdan, J. Fernandes, L. Sutton, A. Banos, O. Reman, B. Lioure, X. Thomas, N. Ifrah, N. Gökbuget, D. Hoelzer, A. Delannoy, R. Bassan, J. Ribera, S. Giebel, H. Dombret, O. Ottmann (2010)
Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line Treatment In Elderly Patients with De Novo Philadelphia Positive ALL (EWALL-PH-01): Kinetic of Response, Resistance and Prognostic SignificanceBlood, 116
-
M. Wetzler, D. Watson, W. Stock, K. Owzar, G. Koval, E. Hoke, J. McCarty, W. Blum, B. Powell, G. Marcucci, C. Bloomfield, C. Linker, R. Larson (2012)
Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance)Blood, 120
-
F. Nicolini, G. Basak, S. Soverini, G. Martinelli, M. Mauro, Martin Müller, A. Hochhaus, C. Chuah, I. Dufva, G. Rege‐Cambrin, G. Saglio, M. Michallet, H. Labussière, S. Morisset, S. Hayette, G. Étienne, E. Olavarría, W. Zhou, S. Peter, J. Apperley, J. Cortes (2011)
Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.Blood, 118 20
-
M. Topp, P. Kufer, N. Gökbuget, M. Goebeler, M. Klinger, S. Neumann, H. Horst, T. Raff, A. Viardot, M. Schmid, M. Stelljes, M. Schaich, Evelyn Degenhard, R. Köhne-Volland, M. Brüggemann, O. Ottmann, H. Pfeifer, T. Burmeister, D. Nagorsen, Margit Schmidt, R. Lutterbuese, C. Reinhardt, P. Baeuerle, M. Kneba, H. Einsele, G. Riethmüller, D. Hoelzer, G. Zugmaier, R. Bargou (2011)
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 18
-
I. Iacobucci, A. Lonetti, F. Messa, D. Cilloni, F. Arruga, E. Ottaviani, S. Paolini, C. Papayannidis, P. Piccaluga, P. Giannoulia, S. Soverini, M. Amabile, A. Poerio, G. Saglio, F. Pane, G. Berton, A. Baruzzi, A. Vitale, S. Chiaretti, G. Perini, R. Foà, M. Baccarani, G. Martinelli (2008)
Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance.Blood, 112 9
-
H. Khoury, J. Cortes, C. Gambacorti-Passerini, Dong-Wook Kim, A. Zaritskey, A. Hochhaus, E. Leip, N. Besson, V. Kelly, T. Brümmendorf (2011)
Activity of Bosutinib by Baseline and Emergent Mutation Status in Philadelphia Chromosome–Positive Leukemia Patients with Resistance or Intolerance to Other Tyrosine Kinase InhibitorsBlood, 118
-
K. Porkka, Perttu Koskenvesa, T. Lundán, J. Rimpiläinen, S. Mustjoki, Richard Smykla, R. Wild, R. Luo, M. Arnán, B. Brethon, L. Eccersley, H. Hjorth-Hansen, M. Höglund, H. Klamová, H. Knutsen, S. Parikh, E. Raffoux, F. Gruber, F. Brito-Babapulle, H. Dombret, Rafael Duarte, E. Elonen, R. Paquette, C. Zwaan, Frank Lee (2008)
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.Blood, 112 4
-
D. Thomas, S. O'brien, S. Faderl, F. Kashani, W. Wierda, M. Andreeff, Rebecca Garris, R. Champlin, J. Cortes, H. Kantarjian (2010)
Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL).Journal of Clinical Oncology, 28
-
OG Ottmann, BJ Druker, CL Sawyers (2002)
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemiasBlood, 100
-
P. Kebriaei, R. Saliba, G. Rondon, Alexandre Chiattone, R. Luthra, P. Anderlini, B. Andersson, E. Shpall, U. Popat, Roy Jones, L. Worth, F. Ravandi, D. Thomas, S. O'brien, H. Kantarjian, M. Lima, S. Giralt, R. Champlin (2012)
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 18 4
-
H. Pfeifer, N. Goekbuget, Christian Völp, A. Hüttmann, M. Lübbert, R. Stuhlmann, J. Dengler, K. Kreuzer, J. Beck, M. Stelljes, M. Schmid, B. Wassmann, L. Leimer, K. Spiekermann, T. Terwey, K. Schäfer‐Eckart, D. Ditz, H. Lindemann, A. Morgner, M. Schaich, T. Burmeister, A. Binckebanck, D. Hoelzer, O. Ottmann (2010)
Long-Term Outcome of 335 Adult Patients Receiving Different Schedules of Imatinib and Chemotherapy as Front-Line Treatment for Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Blood, 116
-
N. Shah, C. Tran, F. Lee, Ping Chen, Derek Norris, C. Sawyers (2004)
Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 305
-
Seok Lee, Dong-Wook Kim, B. Cho, Yoo-Jin Kim, Yoo‐Li Kim, J. Hwang, Y. Park, Ho-Jin Shin, Chiyoung Park, W. Min, Hack‐Ki Kim, Chun‐Choo Kim (2003)
Risk factors for adults with Philadelphia‐chromosome‐positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real‐time quantitative reverse‐transcription polymerase chain reactionBritish Journal of Haematology, 120
-
H. Pfeifer, S. Wystub, A. Binckebanck, B. Wassmann, A. Käbisch, M. Lübbert, L. Leimer, Aristoteles Giagounidis, W. Gassmann, P. Brueck, H. Serve, D. Hoelzer, O. Ottmann (2012)
Imatinib (IM) and Interferon-Alpha (IFN-a) Maintenance Therapy Is Associated with Long-Term DFS in a Subset of Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL)Blood, 120
-
R. Ali, F. Ozkalemkaş, T. Ozcelik, V. Ozkocaman, U. Ozan, Y. Kímya, N. Köksal, Tuna Gülten, T. Yakut, A. Tunalı (2005)
Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission.Leukemia research, 29 8
-
J. Pizzuto, A. Avilés, L. Noriega, J. Niz, M. Mr, F. Romero (1980)
Treatment of acute leukemia during pregnancy: presentation of nine cases.Cancer treatment reports, 64 4-5
-
R. Collins, S. Goldstein, S. Giralt, J. Levine, D. Porter, W. Drobyski, J. Barrett, M. Johnson, A. Kirk, M. Horowitz, P. Parker (2000)
Donor leukocyte infusions in acute lymphocytic leukemiaBone Marrow Transplantation, 26
-
B. Wassmann, N. Gökbuget, U. Scheuring, A. Binckebanck, R. Reutzel, H. Gschaidmeier, D. Hoelzer, O. Ottmann, Gmall Group (2003)
A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblaAnnals of Hematology, 82
-
M. Yanada, I. Sugiura, J. Takeuchi, H. Akiyama, A. Maruta, Y. Ueda, N. Usui, F. Yagasaki, T. Yujiri, M. Takeuchi, K. Nishii, Y. Kimura, S. Miyawaki, H. Narimatsu, Y. Miyazaki, S. Ohtake, I. Jinnai, K. Matsuo, T. Naoe, R. Ohno (2008)
Prospective monitoring of BCR‐ABL1 transcript levels in patients with Philadelphia chromosome‐positive acute lymphoblastic leukaemia undergoing imatinib‐combined chemotherapyBritish Journal of Haematology, 143
-
Y. Chalandon, X. Thomas, S. Hayette, J. Cayuela, C. Abbal, M. Escoffre‐Barbe, S. Maury, S. Leprêtre, F. Witz, L. Benboubker, J. Malfuson, T. Leguay, A. Buzyn, V. Lheritier, M. Béné, M. Lafage, N. Ifrah, H. Dombret (2008)
First Results of the GRAAPH-2005 Study in younger Adult Patients with De Novo Philadelphia Positive Acute Lymphoblastic LeukemiaBlood, 112
-
A. Goldstone, S. Richards, H. Lazarus, M. Tallman, G. Buck, A. Fielding, A. Burnett, R. Chopra, P. Wiernik, L. Foroni, E. Paietta, M. Litzow, D. Marks, J. Durrant, A. McMillan, I. Franklin, S. Luger, N. Ciobanu, J. Rowe (2008)
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin -
T. Burmeister, S. Schwartz, C. Bartram, N. Gökbuget, D. Hoelzer, E. Thiel (2008)
Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group.Blood, 112 3
-
F. Mortuza, M. Papaioannou, I. Moreira, L. Coyle, P. Gameiro, D. Gandini, H. Prentice, A. Goldstone, A. Hoffbrand, L. Foroni (2002)
Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 4
-
David Snyder, A. Nademanee, M. O'donnell, P. Parker, A. Stein, K. Margolin, G. Somlo, A. Molina, R. Spielberger, A. Kashyap, H. Fung, M. Slovak, A. Dagis, R. Negrin, M. Amylon, Blume Kg, S. Forman (1999)
Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remissionLeukemia, 13
-
O. Ottmann, R. Larson, H. Kantarjian, P. Coutre, M. Baccarani, A. Haque, N. Gallagher, F. Giles (2007)
Nilotinib in Patients (pts) with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib.Blood, 110
-
Y. Chalandon, X. Thomas, S. Hayette, J. Cayuela, C. Abbal, F. Huguet, E. Raffoux, T. Leguay, S. Leprêtre, M. Escoffre‐Barbe, S. Maury, C. Berthon, E. Tavernier, J. Lambert, M. Lafage, V. Lheritier, S. Chevret, N. Ifrah, H. Dombret (2012)
Is Less Chemotherapy Detrimental in Adults with Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with High-Dose Imatinib? Results of the Prospective Randomized Graaph-2005 StudyBlood, 120
-
A. Moorman, L. Chilton, J. Wilkinson, Hannah Ensor, N. Bown, S. Proctor (2010)
A population-based cytogenetic study of adults with acute lymphoblastic leukemia.Blood, 115 2
-
O. Ottmann, H. Dombret, G. Martinelli, B. Simonsson, F. Guilhot, R. Larson, G. Rege‐Cambrin, J. Radich, A. Hochhaus, A. Apanovitch, A. Gollerkeri, S. Coutre (2007)
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.Blood, 110 7
-
F. Pane, G. Cimino, B. Izzo, A. Camera, A. Vitale, C. Quintarelli, M. Picardi, G. Specchia, M. Mancini, A. Cuneo, C. Mecucci, G. Martinelli, G. Saglio, B. Rotoli, F. Mandelli, F. Salvatore, R. Foà, for group (2005)
Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemiaLeukemia, 19
-
P. Ault, H. Kantarjian, S. O'brien, S. Faderl, M. Beran, M. Rios, C. Koller, F. Giles, M. Keating, M. Talpaz, J. Cortes (2006)
Pregnancy among patients with chronic myeloid leukemia treated with imatinib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 7
-
S. Soverini, A. Vitale, A. Poerio, A. Gnani, Sabrina Colarossi, I. Iacobucci, G. Cimino, L. Elia, A. Lonetti, M. Vignetti, S. Paolini, G. Meloni, V. Maio, C. Papayannidis, M. Amabile, A. Guarini, M. Baccarani, G. Martinelli, R. Foà (2011)
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosisHaematologica, 96
-
S. Soverini, A. Poerio, A. Ferrarini, I. Iacobucci, M. Sazzini, J. Score, E. Giacomelli, L. Xumerle, Sabrina Colarossi, A. Gnani, F. Castagnetti, F. Palandri, G. Gugliotta, M. Amabile, G. Rosti, M. Baccarani, N. Cross, M. Delledonne, G. Martinelli (2010)
Whole-Transcriptome Sequencing In Chronic Myeloid Leukemia Reveals Novel Gene Mutations That May Be Associated with Disease Pathogenesis and ProgressionBlood, 116
-
E. Tavernier, J. Boiron, F. Huguet, K. Bradstock, N. Vey, T. Kovacsovics, André Delannoy, N. Fegueux, P. Fenaux, A. Stamatoullas, O. Tournilhac, A. Buzyn, O. Reman, C. Charrin, C. Boucheix, J. Gabert, V. Lheritier, J. Vernant, H. Dombret, X. Thomas (2007)
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trialLeukemia, 21
-
H Pfeifer, T Lange, S Wystub (2012)
Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemiaLeukemia, 26
-
B Wassmann, H Pfeifer, W Bethge (2009)
Up-front versus minimal residual disease triggered imatinib after stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukaemia: interim results of a randomized phase III GMALL study (Abstract)Bone Marrow Transplant, 43
-
H. Pfeifer, G. Cazzaniga, O. Spinelli, J. Cayuela, H. Cavé, P. Vandenberghe, C. Chillón, T. Sacha, S. Hayette, Silja Roettgers, T. Lion, L. Foroni, V. Velden, J. Zuna, M. Hermanson, M. Mueller, T. Lange, M. Majewski, I. Bendit, F. Pane, I. Iacobucci, V. Kairisto, C. Homburg, S. Avigad, E. Yeoh, B. Schäfer, A. Fielding, L. Elia, K. Borg, E. Delabesse, S. Schnittger, S. Marković, Volker Werner, N. Goekbuget, D. Hoelzer, J. Dongen, O. Ottmann (2011)
International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL ConsortiaBlood, 118
-
S. Soverini, Sabrina Colarossi, A. Gnani, G. Rosti, F. Castagnetti, A. Poerio, I. Iacobucci, M. Amabile, E. Abruzzese, E. Orlandi, F. Radaelli, F. Ciccone, M. Tiribelli, R. Lorenzo, Clementina Caracciolo, B. Izzo, F. Pane, G. Saglio, M. Baccarani, G. Martinelli (2006)
Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid LeukemiaClinical Cancer Research, 12
-
A. Moore, A. Faisal, D. Castro, V. Bavetsias, Chongbo Sun, B. Atrash, M. Valenti, A. Brandon, Sian Avery, D. Mair, F. Mirabella, J. Swansbury, A. Pearson, P. Workman, J. Blagg, F. Raynaud, S. Eccles, S. Linardopoulos (2012)
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patternsLeukemia, 26
-
AH Goldstone, SM Richards, HM Lazarus (2008)
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)Blood, 111
-
A. Moorman, C. Harrison, G. Buck, S. Richards, L. Secker-Walker, M. Martineau, G. Vance, A. Cherry, R. Higgins, A. Fielding, L. Foroni, E. Paietta, M. Tallman, M. Litzow, P. Wiernik, J. Rowe, A. Goldstone, G. Dewald (2005)
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.Blood, 109 8
-
H. Pfeifer, B. Wassmann, A. Pavlova, L. Wunderle, J. Oldenburg, A. Binckebanck, T. Lange, A. Hochhaus, S. Wystub, P. Brück, D. Hoelzer, O. Ottmann (2007)
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).Blood, 110 2
-
C. Mullighan, X. Su, Jinghui Zhang, I. Radtke, Letha Phillips, C. Miller, Jing Ma, Wei Liu, Cheng Cheng, B. Schulman, B. Schulman, R. Harvey, R. Harvey, I. Chen, I. Chen, R. Clifford, W. Carroll, G. Reaman, W. Bowman, M. Devidas, D. Gerhard, Wenjian Yang, M. Relling, S. Shurtleff, D. Campana, M. Borowitz, C. Pui, Malcolm Smith, S. Hunger, C. Willman, C. Willman, J. Downing (2009)
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.The New England journal of medicine, 360 5
-
Y Chelghoum, N Vey, E Raffoux (2005)
Acute leukemia during pregnancy: a report on 37 patients and a review of the literatureCancer, 104
-
G. Martinelli, I. Iacobucci, C. Storlazzi, M. Vignetti, F. Paoloni, D. Cilloni, S. Soverini, A. Vitale, S. Chiaretti, G. Cimino, C. Papayannidis, S. Paolini, L. Elia, P. Fazi, G. Meloni, S. Amadori, G. Saglio, F. Pane, M. Baccarani, R. Foà (2009)
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 31
-
F. Millot, M. Cividin, F. Brizard, J. Chomel, F. Mechinaud, F. Guilhot (2009)
Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemiaPediatric Blood & Cancer, 52
-
M. Lilly, O. Ottmann, N. Shah, R. Larson, J. Reiffers, G. Ehninger, M. Müller, A. Charbonnier, E. Bullorsky, H. Dombret, Mary Bradley-Garelik, Chao Zhu, G. Martinelli (2010)
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph‐positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 studyAmerican Journal of Hematology, 85
-
S. Mizuta, Keitaro Matsuo, F. Yagasaki, T. Yujiri, Yoshihiro Hatta, Yukihiko Kimura, Yasunori Ueda, H. Kanamori, Noriko Usui, Hideki Akiyama, Y. Miyazaki, S. Ohtake, Y. Atsuta, Hisashi Sakamaki, Keisei Kawa, Yasuo Morishima, K. Ohnishi, T. Naoe, Ryuzo Ohno (2011)
Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR–ABL-positive acute lymphoblastic leukemiaLeukemia, 25
-
H Pfeifer, C Wettner, B Wassmann (2012)
Long term follow up of elderly patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL): updated results of the GMALL elderly trials. (Abstract)Haematologica, 97
-
S. Soverini, C. Benedittis, K. Polakova, A. Broučková, F. Castagnetti, C. Papayannidis, G. Gugliotta, F. Palandri, H. Klamová, I. Iacobucci, C. Venturi, F. Cattina, P. Bresciani, V. Coluccio, M. Salvucci, M. Tiribelli, G. Binotto, T. Intermesoli, M. Luppi, M. Bochicchio, E. Ottaviani, D. Russo, G. Rosti, M. Baccarani, G. Martinelli (2012)
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical ImplicationsBlood, 120
-
H. Pfeifer, B. Wassmann, W. Bethge, J. Dengler, M. Bornhäuser, M. Stadler, D. Beelen, A. Günther, V. Vučinić, T. Burmeister, M. Stelljes, R. Schwerdtfeger, Kerstin Schaefer-Eckhart, P. Bader, H. Kreyenberg, P. Schuld, H. Serve, D. Hoelzer, N. Goekbuget, O. Ottmann (2011)
Updated Long-Term Results of a Randomized Comparison of Prophylactic and Pre-Emptive Imatinib Following Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)Blood, 118
-
E. Cardonick, Audrey Iacobucci (2004)
Use of chemotherapy during human pregnancy.The Lancet. Oncology, 5 5
-
E. Castillo, R. Al-Rajabi, D. Pandya, P. Varadarajan, K. Kelly, R. Swords, A. Tharian, M. Kraus, S. Padmanabhan (2010)
A Pilot Study of the Combination of Nilotinib and Hyper-CVAD for Philadelphia Chromosome Positive Acute Lymphocytic Leukemia and Lymphoid Blast Crisis Chronic Myelogenous LeukemiaBlood, 116
-
J. Cortes, H. Kantarjian, T. Brümmendorf, Dong-Wook Kim, A. Turkina, Zhi-xiang Shen, R. Pasquini, H. Khoury, S. Arkin, A. Volkert, N. Besson, R. Abbas, Junyuan Wang, E. Leip, C. Gambacorti-Passerini (2011)
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.Blood, 118 17
-
F. Ravandi, S. O'Brien, D. Thomas, S. Faderl, Dan Jones, Rebecca Garris, S. Dara, J. Jorgensen, P. Kebriaei, R. Champlin, G. Borthakur, J. Burger, A. Ferrajoli, G. Garcia-Manero, W. Wierda, J. Cortes, H. Kantarjian (2010)
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.Blood, 116 12
-
N. Takayama, N. Sato, S. O’Brien, Y. Ikeda, S. Okamoto (2002)
Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome‐positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluidBritish Journal of Haematology, 119
-
A Stein, M O’Donnell, D Snyder (2009)
Reduced-intensity stem cell transplantation for high-risk acute lymphoblastic leukaemiaBiol Blood Marrow Transplant, 15
-
S. Rives, J. Estella, P. Gómez, M. López-Duarte, Purificación Miguel, A. Verdeguer, M. Moreno, J. Vivanco, J. Couselo, R. Fernández‐Delgado, M. Maldonado, M. Tasso, B. López-Ibor, F. Lendinez, R. López-Almaráz, J. Uriz, M. Melo, A. Fernández-Teijeiro, Isidoro Rodríguez, I. Badell (2011)
Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome‐positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL‐94, ALL‐99 and ALL‐2005British Journal of Haematology, 154
-
A. Fielding (2010)
How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia.Blood, 116 18
-
M. Yazaki, M. Andoh, T. Ito, T. Ohno, Y. Wada (1997)
Successful prevention of hematological relapse for a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation by donor leukocyte infusionBone Marrow Transplantation, 19
-
R. Martino, S. Giralt, M. Caballero, S. Mackinnon, P. Corradini, F. Fernández-Avilés, J. Miguel, J. Sierra (2003)
Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study.Haematologica, 88 5
-
R. Ram, R. Storb, B. Sandmaier, D. Maloney, A. Woolfrey, M. Flowers, M. Maris, G. Laport, T. Chauncey, T. Lange, A. Langston, B. Storer, G. Georges (2011)
Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemiaHaematologica, 96
-
C. Preudhomme, N. Henic, B. Cazin, J. Laï, M. Berthéas, M. Vanrumbeke, F. Lemoine, J. Jouet, E. Deconninck, B. Nelken, A. Cosson, P. Fenaux (1997)
Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL)Leukemia, 11
-
J. Cortes, Dong-Wook Kim, J. Pinilla-Ibarz, P. Coutre, R. Paquette, C. Chuah, F. Nicolini, J. Apperley, H. Khoury, M. Talpaz, J. Dipersio, D. DeAngelo, E. Abruzzese, D. Réa, M. Baccarani, Martin Müller, C. Gambacorti-Passerini, S. Wong, S. Lustgarten, V. Rivera, T. Clackson, C. Turner, F. Haluska, F. Guilhot, M. Deininger, A. Hochhaus, T. Hughes, J. Goldman, N. Shah, H. Kantarjian (2012)
A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE TrialBlood, 120
-
S. Faderl, H. Kantarjian, D. Thomas, J. Cortes, F. Giles, S. Pierce, M. Albitar, Z. Estrov (2000)
Outcome of Philadelphia Chromosome-Positive Adult Acute Lymphoblastic LeukemiaLeukemia & Lymphoma, 36
-
B Wassmann, N Gökbuget, U Scheuring (2003)
A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) (CSTI571ADE 10)Ann Hematol, 82
-
A. Fielding, S. Richards, R. Chopra, H. Lazarus, M. Litzow, G. Buck, I. Durrant, S. Luger, D. Marks, I. Franklin, A. McMillan, M. Tallman, J. Rowe, A. Goldstone (2007)
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.Blood, 109 3
-
E. Reynoso, F. Shepherd, H. Messner, H. Farquharson, M. Garvey, M. Baker (1987)
Acute leukemia during pregnancy: the Toronto Leukemia Study Group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 5 7
-
E. Heartin, S. Walkinshaw, R. Clark (2004)
Successful Outcome of Pregnancy in Chronic Myeloid Leukaemia Treated with ImatinibLeukemia & Lymphoma, 45
-
M. Hensley, J. Ford (2003)
Imatinib treatment: specific issues related to safety, fertility, and pregnancy.Seminars in hematology, 40 2 Suppl 2
-
R. Bassan, G. Rossi, E. Pogliani, E. Bona, E. Angelucci, I. Cavattoni, G. Lambertenghi‐Deliliers, F. Mannelli, A. Levis, F. Ciceri, D. Mattei, E. Borlenghi, E. Terruzzi, C. Borghero, C. Romani, O. Spinelli, M. Tosi, E. Oldani, T. Intermesoli, A. Rambaldi (2010)
Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 22
-
S. Alkindi, D. Dennison, A. Pathare (2005)
Imatinib in pregnancyEuropean Journal of Haematology, 74
-
M Eefting, C Halkes, S Kersting (2012)
Excellent outcome after T cell depleted allogeneic stem cell transplantation with pre-emptive donor lymphocyte infusion for Philadelphia-positive acute lymphoblastic leukemia in first remission. (Abstract)Haematologica, 97
-
Y. Ishida, K. Terasako, K. Oshima, K. Sakamoto, M. Ashizawa, Miki Sato, M. Kikuchi, S. Kimura, H. Nakasone, S. Okuda, S. Kako, R. Yamazaki, J. Nishida, Y. Kanda (2010)
Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantationInternational Journal of Hematology, 92
-
A. Barrett, M. Horowitz, R. Ash, K. Atkinson, R. Gale, J. Goldman, P. Henslee‐Downey, R. Herzig, B. Speck, F. Zwaan, M. Bortin (1992)
Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.Blood, 79 11
-
Dae-Young Kim, Y. Joo, Je-Hwan Lee, Jung-Hee Lee, D. Kim, C. Jung, Inho Kim, Sung-Soo Yoon, Deok-Hwan Yang, Je-Jung Lee, Y. Kim, Y. Mun, Hawk Kim, S. Sohn, W. Lee, J. Won, M. Hyun, Jae Lee, H. Chi, K. Lee (2011)
Nilotinib Combined with Multi-Agent Chemotherapy for Adult Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Interim Results of Korean Adult ALL Working Party Phase 2 StudyBlood, 118
-
V. Bachanova, M. Verneris, T. Defor, C. Brunstein, D. Weisdorf (2009)
Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation.Blood, 113 13
-
B. Wassmann, H. Pfeifer, M. Stadler, Martin Bornhaüser, G. Bug, U. Scheuring, P. Brück, M. Stelljes, R. Schwerdtfeger, N. Basara, J. Perz, D. Bunjes, G. Ledderose, R. Mahlberg, A. Binckebanck, H. Gschaidmeier, D. Hoelzer, O. Ottmann (2005)
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).Blood, 106 2
-
M. Talpaz, N. Shah, H. Kantarjian, N. Donato, J. Nicoll, R. Paquette, J. Cortes, S. O'brien, C. Nicaise, E. Bleickardt, M. Blackwood-Chirchir, V. Iyer, Tai-Tsang Chen, F. Huang, A. DeCillis, C. Sawyers, C. Sawyers (2006)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.The New England journal of medicine, 354 24
-
M. Yanada, T. Naoe, H. Iida, H. Sakamaki, T. Sakura, H. Kanamori, Y. Kodera, S. Okamoto, Y. Kanda, H. Sao, O. Asai, K. Nakai, A. Maruta, K. Kishi, T. Furukawa, Y. Atsuta, K. Yamamoto, J. Tanaka, S. Takahashi (2005)
Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host diseaseBone Marrow Transplantation, 36
-
J. Cortes, Dong-Wook Kim, J. Pinilla, P. Coutre, C. Chuah, E. Franck, Nicolini, R. Paquette, J. Apperley, J. Dipersio, H. Khoury, D. Réa, M. Talpaz, D. DeAngelo, E. Abruzzese, M. Baccarani, M. Mueller, C. Gambacorti-Passerini, S. Wong, S. Lustgarten, C. Turner, Victor, Rivera, T. Clackson, F. Haluska, H. Kantarjian (2011)
Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I MutationBlood, 118
-
T. O'hare, D. Walters, E. Stoffregen, Taiping Jia, P. Manley, J. Mestan, S. Cowan-Jacob, F. Lee, M. Heinrich, M. Deininger, B. Druker (2005)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.Cancer research, 65 11
-
P. Carpenter, D. Snyder, M. Flowers, J. Sanders, T. Gooley, P. Martin, F. Appelbaum, J. Radich (2007)
Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.Blood, 109 7
-
H. Dombret, J. Gabert, J. Boiron, F. Rigal-huguet, D. Blaise, X. Thomas, A. Delannoy, A. Buzyn, C. Bilhou-Nabera, J. Cayuela, P. Fenaux, J. Bourhis, N. Fegueux, C. Charrin, C. Boucheix, V. Lheritier, H. Esperou, E. Macintyre, J. Vernant, D. Fiére (2002)
Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial.Blood, 100 7
-
S. Forman, M. O'donnell, A. Nademanee, D. Snyder, P. Bierman, G. Schmidt, J. Fahey, A. Stein, P. Parker, K. Blume (1987)
Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.Blood, 70 2
-
F. Keil, P. Kalhs, O. Haas, G. Fritsch, Elisabeth Reiter, C. Mannhalter, K. Lechner, G. Leitner, H. Greinix (1997)
Relapse of Philadelphia chromosome positive acute lymphoblastic leukaemia after marrow transplantation: sustained molecular remission after early and dose‐escalating infusion of donor leucocytesBritish Journal of Haematology, 97
-
G. Laport, J. Alvarnas, J. Palmer, D. Snyder, M. Slovak, A. Cherry, R. Wong, R. Negrin, K. Blume, S. Forman (2008)
Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen.Blood, 112 3
-
A. Delannoy, E. Delabesse, V. Lheritier, S. Castaigne, F. Rigal-huguet, E. Raffoux, F. Garban, O. Legrand, S. Bologna, V. Dubruille, P. Turlure, O. Reman, M. Delain, F. Isnard, D. Coso, P. Raby, A. Buzyn, S. Caillères, S. Darré, C. Fohrer, A. Sonet, C. Bilhou-Nabera, M. Béné, H. Dombret, P. Berthaud, X. Thomas, for Leukemia (2006)
Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 studyLeukemia, 20
-
K. Matsue, T. Tabayashi, K. Yamada, M. Takeuchi (2002)
Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaBone Marrow Transplantation, 29
-
D Thomas, H Kantarjian, T Smith (1999)
Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapyCancer, 86
-
O. Ottmann, B. Wassmann, H. Pfeifer, Aristoteles Giagounidis, M. Stelljes, U. Dührsen, M. Schmalzing, L. Wunderle, A. Binckebanck, D. Hoelzer (2007)
Imatinib compared with chemotherapy as front‐line treatment of elderly patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL)Cancer, 109
-
R. Foà, A. Vitale, M. Vignetti, G. Meloni, A. Guarini, M. Propris, L. Elia, F. Paoloni, P. Fazi, G. Cimino, F. Nobile, F. Ferrara, C. Castagnola, S. Sica, P. Leoni, E. Zuffa, C. Fozza, M. Luppi, A. Candoni, I. Iacobucci, S. Soverini, F. Mandelli, G. Martinelli, M. Baccarani (2011)
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.Blood, 118 25
-
D. Thomas, H. Kantarjian, T. Smith, C. Koller, J. Cortes, S. O'brien, F. Giles, J. Gajewski, S. Pierce, M. Keating (1999)
Primary refractory and relapsed adult acute lymphoblastic leukemiaCancer, 86
- Publisher
- Springer Journals
- Copyright
- Copyright © 2013 by Springer Science+Business Media New York
- Subject
- Medicine & Public Health; Hematology; Oncology; Geriatrics/Gerontology
- ISSN
- 1558-8211
- eISSN
- 1558-822X
- DOI
- 10.1007/s11899-013-0155-4
- pmid
- 23475624
- Publisher site
- See Article on Publisher Site
Abstract
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is characterized by expression of oncogenic fusion product BCR-ABL1, resulting from reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11.2)]. Previously perceived to confer poor outcome with at least 10 % lower chance of remission than standard-risk ALL. With the advent of targeted BCR-ABL specific tyrosine-kinase inhibitors (TKIs), higher remission rates were achieved, thus allowing more patients to proceed with the definitive treatment modality—allogeneic hematopoietic stem cell transplantation (alloHSCT). Prime challenges to treatment of Ph+ ALL include appropriate integration of TKIs into remission induction chemotherapeutic regimes, appropriate understanding and implementation of BCR-ABL monitoring for guiding therapeutic intervention(s), and minimizing transplant-related toxicities.
Journal
Current Hematologic Malignancy Reports – Springer Journals
Published: Mar 9, 2013